All In Biotech

NDA 022497 · Twi Pharms

Forfivo Xl

Bupropion Hydrochloride · Oral

Last checked: Nov 20, 2026Latest source record: Nov 5, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2011

Nov 10, 2011

Approved uses

1

Original approval plus efficacy supplements

Registered trials

440

96 Phase 3, 24 recruiting

FAERS reports

17,189

10,285 serious, 1,996 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS SUICIDALITY AND ANTIDEPRESSANT DRUGS Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials. These trials did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in subjects over age 24; there was a reduction in risk with antidepressant use in subjects aged 65 and older [see Warnings and Precautions (5.1)] . In patients of all ages who are started on antidepressant therapy, monitor closely for worsening and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber. Bupropion hydrochloride extended-release tablets (XL) is not approved for use in pediatric patients [see Warnings and Precautions (5.1)] . WARNING: SUICIDAL THOUGHTS AND...

What it is approved for

From the label in effect Feb 4, 2026.

Bupropion hydrochloride extended-release tablets (XL) are indicated for the treatment of major depressive disorder (MDD), as defined by the Diagnostic and Statistical Manual (DSM). The efficacy of the immediate-release formulation of bupropion was established in two 4-week controlled inpatient trials and one 6-week controlled outpatient trial of adult patients with MDD. The efficacy of the sustained-release formulation of bupropion in the maintenance treatment of MDD was established in a long-term (up to 44 weeks), placebo-controlled trial in patients who had responded to bupropion in an 8-week study of acute treatment [see Clinical Studies (14)] . The physician who elects to use bupropion hydrochloride extended-release tablets (XL) for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient. Bupropion hydrochloride extended-release tablets (XL) are an aminoketone antidepressant indicated for the treatment of major depressive disorder (MDD) (1). The efficacy was established in two 4-week trials, one 6-week trial with bupropion immediate-release formulation, and one maintenance trial with bupropion sustained-release formulation, all in adults (14). Periodically re-evaluate long-term usefulness for the individual patient.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • FORFIVO XL · BUPROPION HYDROCHLORIDE 450MG · TABLET, EXTENDED RELEASE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Bupropion" as an intervention, any sponsor and status, largest first.

All 440 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,998
  • headache1,498
  • fatigue1,404
  • depression1,350
  • nausea1,207
  • off label use1,072
  • pain988
  • intentional overdose897
  • anxiety886
  • drug interaction864
  • rash849
  • toxicity to various agents823

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004183
2005196
2006169
2007246
2008317
2009303
2010209
2011387
2012565
2013302
2014323
2015334
2016403
2017659
2018527
2019806
2020776
20211,240
20221,749
20231,733
20242,452
20251,843
20261,467

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Forfivo XL (Bupropion HCl)

2024 spending

$237K

Beneficiaries

97

355 claims

Per beneficiary

$2,440

$14.64 per unit

View as table
YearSpending
2020$781,850
2021$634,599
2022$544,151
2023$413,553
2024$236,682

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,202 on PubMed

Sponsor: Twi Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.